Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma

Author:

Teishima Jun,Murata Daiki,Yukihiro Kazuma,Sekino Yohei,Inoue Shogo,Hayashi Tetsutaro,Mita Koji,Hasegawa Yasuhisa,Kato Masao,Kajiwara Mitsuru,Shigeta Masanobu,Maruyama Satoshi,Moriyama Hiroyuki,Fujiwara Seiji,Matsubara Akio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology,Oncology,Reproductive Medicine

Reference23 articles.

1. Cancer statistics, 2018;CA Cancer J Clin,2018

2. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-Medicare database analysis;Clin Genitourin Cancer,2017

3. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era;PLoS One,2013

4. Nivolumab versus everolimus in advanced renal-cell carcinoma;N Engl J Med,2015

5. Updated European association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma;Eur Urol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3